
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a commercial-stage biopharmaceutical company with a diverse pipeline of drug candidates in various stages of development. Despite some recent setbacks in clinical trials and financial uncertainties, the company has a positive outlook due to their strong portfolio and potential for future growth. Their drug candidate Mosliciguat has shown promising results in reducing pulmonary vascular resistance and improving patient outcomes, and this could expand the overall treated population for Roivant. Additionally, the company has a strong valuation and potential for success in their multiple indications, which could contribute to long-term upside. While there are some risks due to competition and unvalidated technologies, Roivant's potential for success in their current pipeline positions them well for future growth and success.
Bears say
Roivant Sciences is in a promising industry, but their drug candidates do not have a strong track record or enough data to support their potential. The company's current leading drug candidate, VTAMA, only targets a specific and limited condition, and their other candidates, such as Batoclimab and Brepocitinib, have concerns surrounding their safety and effectiveness. The lack of clear and proven clinical benefits may hinder the company's long-term success in the market. Additionally, with competitors such as argenx's Vyvgart having a more established safety profile, Roivant Sciences may struggle to differentiate itself and gain market share.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares